OR WAIT null SECS
December 03, 2021
The companies will focus on the rapid development of polymerase chain reaction assays for emerging pathogens and potential health threats, including biological threats.
December 01, 2021
Analytical methods need a boost to ensure quality control for cell and gene therapies.
November 10, 2021
Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.
November 08, 2021
Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.
November 04, 2021
Gentronix has expanded it lab facilities and increased capacity for genetic, ocular, and skin toxicology testing.
November 03, 2021
The increased flow of data from laboratory studies requires a data management strategy to optimize study success.
November 02, 2021
Automatic visual inspection machines and artificial intelligence highlight inspection deficits for parenteral containers and units.
October 02, 2021
Although stability testing programs for small-molecule drugs and biologics are often perceived as similar, stability programs for biologics are far more complex.
September 15, 2021
A simplified process flow with associated definitions for pharmaceutical sampling and testing is proposed.
Inconsistent sampling and testing processes can lead to errors, resulting in data integrity issues and potentially incorrect decisions about pharmaceutical quality.